Segment Information

12 Months Ended

Dec. 31, 2012

Segment Information

Segment Information

Note 10. Segment Information

        The Company operates in one business segment, which primarily focuses on the development and global commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The Company's Oncotype DX breast and colon tests have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. As of December 31, 2012, the majority of the Company's product revenues have been derived from sales of one product, the Oncotype DX breast cancer test.

        As of December 31, 2012, the majority of the Company's tests have been delivered to physicians in the United States. All Oncotype DX tests are processed in the Company's clinical reference laboratory facility in Redwood City, California. The following table summarizes total revenues from customers, payors and collaboration partners by geographic region (in thousands). Product revenues are attributed to countries based on ship-to location. Contract revenues are attributed to countries based on the location of the collaboration partner.

	Year Ended December 31,
	2012		2011		2010
	(In thousands)
United States	$	207,508	$	187,300	$	168,021
Outside of the United States		27,665		18,811		10,080
Total revenues	$	235,173	$	206,111	$	178,101

        Medicare payments accounted for approximately 22%, 22% and 21% of the Company's product revenues for the years ended December 31, 2012, 2011 and 2010, respectively. There were no other customers or payors who individually accounted for 10% or more of product revenues.